MIGENIX Completes Enrollment of Celgosivir (MX-3253) Phase IIb HCV Combination S

[Guest guest]

MIGENIX Completes Enrollment of Celgosivir (MX-3253) Phase IIb HCV

Combination Study

VANCOUVER/SAN DIEGO, June 15 /PRNewswire-FirstCall/ - MIGENIX Inc.

(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious

and degenerative diseases, has completed enrollment in a Phase IIb study of

celgosivir (MX-3253) in combination with PEG-INTRON® (peginterferon alfa-

2b), and PEGETRON (peginterferon alfa-2b plus ribavirin) for the

treatment of hepatitis C virus (HCV) infection in genotype 1 patients who

were non- responders or partial responders to previous treatment with

pegylated interferon-based therapy. A total of 57 subjects have been

enrolled. The subjects will be treated for 12 weeks and results are

expected to be available in October 2006. This study is being supported in

part through an agreement with Schering-Plough.

AnnKatrin sen, M.D., Vice President of Clinical Development for

MIGENIX commented, " With 57 patients enrolled, this study is well-powered

to detect a treatment effect as measured by the change in mean viral load

over a 12-week treatment period. This proof-of-concept study in conjunction

with our planned viral kinetic study in naive patients will provide

substantial information about the benefit of celgosivir in combination with

peginterferon alfa-2b, with and/or without ribavirin in the treatment of

HCV. "

Jim DeMesa, M.D., President and CEO of MIGENIX added, " During the next

12 months we expect results from two Phase II studies of celgosivir in the

treatment of HCV patients and a pivotal Phase III study of CPI-226 in the

prevention of catheter-related infections. These clinical results, along

with the progress we are making in advancing several pipeline programs,

provide us many value-driving opportunities for the future. "

About Celgosivir

Celgosivir is an alpha-glucosidase I inhibitor and is currently the

only oral anti-HCV drug in clinical development that acts on host-directed

glycosylation. In preclinical studies, celgosivir has demonstrated strong

synergy with interferon-alpha (with or without ribavirin) and other drugs

in development for the treatment of HCV (e.g. polymerase inhibitors) and

has the potential to be included as part of a combination therapeutic

approach to improve efficacy.

About the Phase IIb Combination Study in HCV Non-Responder/Partial

Responder Patients

The Phase IIb study is designed to determine over 12 weeks of treatment

the efficacy, safety, and tolerability of celgosivir in combination with

PEG-INTRON® (peginterferon alfa-2b), and PEGETRON (peginterferon

alfa-2b plus ribavirin), in HCV-positive (genotype 1) patients who were

non-responders or partial responders to previous treatment with pegylated

interferon-based therapy. The study is a randomized, multi-center,

active-controlled, 12 week evaluation of celgosivir in three treatment arms

(up to 20 patients in each treatment arm): (i) celgosivir plus PEGETRON

(3-way combination); (ii) celgosivir plus PEG-INTRON® (2-way

combination); and (iii) placebo plus peginterferon alfa-2b plus ribavirin

(control). A total of 57 subjects have been enrolled into the study. The

Phase IIb study is supported in part through an agreement with

Schering-Plough Corporation. Schering-Plough is contributing (a) the supply

of PEG-INTRON® and PEGETRON and ( certain technical and laboratory

support and other services for the studies. In addition, the agreement

grants Schering-Plough limited periods of exclusivity for data review

following the clinical trial results and for the negotiation of a license

agreement.

About HCV

HCV, the most common chronic blood-borne infection in the United

States, causes inflammation of the liver and may progress to more serious

complications such as cirrhosis of the liver, liver cancer and death.

Approximately 2.7 million people in the United States are chronically

infected with HCV, and the Centers for Disease Control and Prevention (CDC)

estimates that by the year 2010, the number of deaths attributed annually

to HCV could surpass that due to HIV/AIDS in the US. Worldwide, the World

Health Organization estimates that 170 million individuals have chronic HCV

infection, with 3 to 4 million new infections each year.

Therapy for HCV currently employs a drug combination approach, which is

anticipated to continue in the future. The current standard of care for

chronic hepatitis C is pegylated interferon combined with ribavirin, which

fails to provide a satisfactory outcome for approximately 50% of patients

infected with HCV genotype 1. In addition, these drugs can cause

significant side effects that limit tolerance to therapy, or a frequent

lack of sustained treatment response.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and

enriching life by developing and commercializing drugs in the areas of

infectious and degenerative diseases. The Company's clinical programs

include drug candidates for the treatment of chronic hepatitis C infections

(Phase II), the prevention of catheter-related infections (Phase III), the

treatment of neurodegenerative diseases (Phase I) and the treatment of acne

(Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada

with US operations in San Diego, California. Additional information can be

found at http://www.migenix.com.

" Jim DeMesa "

M. DeMesa, M.D.

President & CEO

CONTACTS

Art Ayres Dian Griesel, Ph.D.

MIGENIX Inc. Investor Relations Group

Tel: (604) 221-9666 Ext. 233 Tel: (212) 825-3210

aayres@... Theproteam@...

FORWARD-LOOKING STATEMENTS

Certain statements in this news release contain forward-looking

statements or information under applicable Canadian and United States

securities legislation. All statements or information other than statements

of historical fact may be deemed to be forward-looking statements or

information. Forward-looking statements frequently, but not always, use the

words " intends " , " plans " , " believes " , " anticipates " or " expects " or similar

words; that events " will " , " may " , " could " or " should " occur; and/or include

statements or information concerning our strategies, goals, plans and

expectations. Forward-looking statements or information in this news

release include, but are not limited to statements or information

concerning: results from the celgosivir Phase IIb combination study in

non-responder and partial responder HCV infected patients being available

in October 2006; and during the next 12 months having results from two

Phase II studies of celgosivir in the treatment of HCV patients and from a

pivotal Phase III study of CPI-226 in the prevention of catheter-related

infections. We may not actually achieve the plans, intentions or

expectations disclosed in our forward-looking statements or information and

you should not place undue reliance on our forward-looking statements or

information. Factors that could cause actual events or results expressed or

implied by such forward looking statements to differ materially from any

future results expressed or implied by such statements or information

include, but are not limited to: uncertainties related to early stage of

technology and product development; dependence on corporate collaborations;

uncertainties as to future expense levels and the possibility of

unanticipated costs or expenses or cost overruns, the possibility that

opportunities will arise that require more cash than presently anticipated

and other uncertainties related to predictions of future cash requirements;

uncertainties as to the requirement that a drug be found to be safe and

effective after extensive clinical trials and the possibility that the

results of such trials, if commenced and completed, will not establish the

safety or efficacy of our products; risks relating to requirements for

approvals by government agencies such as the FDA and/or Health Canada

before products can be tested in clinical trials and ultimately marketed;

the possibility that such government agency approvals will not be obtained

in a timely manner or at all or will be conditioned in a manner that would

impair our ability to advance development and/or market the product

successfully; management of growth; dependence on key personnel; the

possibility that we will not successfully develop any products; the

possibility that advances by competitors will cause our proposed products

not to be viable, the risk that our patents could be invalidated or

narrowed in scope by judicial actions or that our technology could infringe

the patent or other intellectual property rights of third parties; the

possibility that any products successfully developed by us will not achieve

market acceptance; and other risks and uncertainties which may not be

described herein. Certain of these factors and other factors are described

in detail in the Company's Annual Information Form and Annual Report on

Form 20-F and other filings with the Canadian securities regulatory

authorities and the U.S. Securities & Exchange Commission. Forward-looking

statements are based on our current expectations and MIGENIX assumes no

obligations to update such information to reflect later events or

developments.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

SOURCE MIGENIX Inc.

http://www.prnewswire.com/news/index_mail.shtml?Account=HEA & Template=hea_ind.htm\

l

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

MIGENIX Completes Enrollment of Celgosivir (MX-3253) Phase IIb HCV

Combination Study

VANCOUVER/SAN DIEGO, June 15 /PRNewswire-FirstCall/ - MIGENIX Inc.

(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious

and degenerative diseases, has completed enrollment in a Phase IIb study of

celgosivir (MX-3253) in combination with PEG-INTRON® (peginterferon alfa-

2b), and PEGETRON (peginterferon alfa-2b plus ribavirin) for the

treatment of hepatitis C virus (HCV) infection in genotype 1 patients who

were non- responders or partial responders to previous treatment with

pegylated interferon-based therapy. A total of 57 subjects have been

enrolled. The subjects will be treated for 12 weeks and results are

expected to be available in October 2006. This study is being supported in

part through an agreement with Schering-Plough.

AnnKatrin sen, M.D., Vice President of Clinical Development for

MIGENIX commented, " With 57 patients enrolled, this study is well-powered

to detect a treatment effect as measured by the change in mean viral load

over a 12-week treatment period. This proof-of-concept study in conjunction

with our planned viral kinetic study in naive patients will provide

substantial information about the benefit of celgosivir in combination with

peginterferon alfa-2b, with and/or without ribavirin in the treatment of

HCV. "

Jim DeMesa, M.D., President and CEO of MIGENIX added, " During the next

12 months we expect results from two Phase II studies of celgosivir in the

treatment of HCV patients and a pivotal Phase III study of CPI-226 in the

prevention of catheter-related infections. These clinical results, along

with the progress we are making in advancing several pipeline programs,

provide us many value-driving opportunities for the future. "

About Celgosivir

Celgosivir is an alpha-glucosidase I inhibitor and is currently the

only oral anti-HCV drug in clinical development that acts on host-directed

glycosylation. In preclinical studies, celgosivir has demonstrated strong

synergy with interferon-alpha (with or without ribavirin) and other drugs

in development for the treatment of HCV (e.g. polymerase inhibitors) and

has the potential to be included as part of a combination therapeutic

approach to improve efficacy.

About the Phase IIb Combination Study in HCV Non-Responder/Partial

Responder Patients

The Phase IIb study is designed to determine over 12 weeks of treatment

the efficacy, safety, and tolerability of celgosivir in combination with

PEG-INTRON® (peginterferon alfa-2b), and PEGETRON (peginterferon

alfa-2b plus ribavirin), in HCV-positive (genotype 1) patients who were

non-responders or partial responders to previous treatment with pegylated

interferon-based therapy. The study is a randomized, multi-center,

active-controlled, 12 week evaluation of celgosivir in three treatment arms

(up to 20 patients in each treatment arm): (i) celgosivir plus PEGETRON

(3-way combination); (ii) celgosivir plus PEG-INTRON® (2-way

combination); and (iii) placebo plus peginterferon alfa-2b plus ribavirin

(control). A total of 57 subjects have been enrolled into the study. The

Phase IIb study is supported in part through an agreement with

Schering-Plough Corporation. Schering-Plough is contributing (a) the supply

of PEG-INTRON® and PEGETRON and ( certain technical and laboratory

support and other services for the studies. In addition, the agreement

grants Schering-Plough limited periods of exclusivity for data review

following the clinical trial results and for the negotiation of a license

agreement.

About HCV

HCV, the most common chronic blood-borne infection in the United

States, causes inflammation of the liver and may progress to more serious

complications such as cirrhosis of the liver, liver cancer and death.

Approximately 2.7 million people in the United States are chronically

infected with HCV, and the Centers for Disease Control and Prevention (CDC)

estimates that by the year 2010, the number of deaths attributed annually

to HCV could surpass that due to HIV/AIDS in the US. Worldwide, the World

Health Organization estimates that 170 million individuals have chronic HCV

infection, with 3 to 4 million new infections each year.

Therapy for HCV currently employs a drug combination approach, which is

anticipated to continue in the future. The current standard of care for

chronic hepatitis C is pegylated interferon combined with ribavirin, which

fails to provide a satisfactory outcome for approximately 50% of patients

infected with HCV genotype 1. In addition, these drugs can cause

significant side effects that limit tolerance to therapy, or a frequent

lack of sustained treatment response.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and

enriching life by developing and commercializing drugs in the areas of

infectious and degenerative diseases. The Company's clinical programs

include drug candidates for the treatment of chronic hepatitis C infections

(Phase II), the prevention of catheter-related infections (Phase III), the

treatment of neurodegenerative diseases (Phase I) and the treatment of acne

(Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada

with US operations in San Diego, California. Additional information can be

found at http://www.migenix.com.

" Jim DeMesa "

M. DeMesa, M.D.

President & CEO

CONTACTS

Art Ayres Dian Griesel, Ph.D.

MIGENIX Inc. Investor Relations Group

Tel: (604) 221-9666 Ext. 233 Tel: (212) 825-3210

aayres@... Theproteam@...

FORWARD-LOOKING STATEMENTS

Certain statements in this news release contain forward-looking

statements or information under applicable Canadian and United States

securities legislation. All statements or information other than statements

of historical fact may be deemed to be forward-looking statements or

information. Forward-looking statements frequently, but not always, use the

words " intends " , " plans " , " believes " , " anticipates " or " expects " or similar

words; that events " will " , " may " , " could " or " should " occur; and/or include

statements or information concerning our strategies, goals, plans and

expectations. Forward-looking statements or information in this news

release include, but are not limited to statements or information

concerning: results from the celgosivir Phase IIb combination study in

non-responder and partial responder HCV infected patients being available

in October 2006; and during the next 12 months having results from two

Phase II studies of celgosivir in the treatment of HCV patients and from a

pivotal Phase III study of CPI-226 in the prevention of catheter-related

infections. We may not actually achieve the plans, intentions or

expectations disclosed in our forward-looking statements or information and

you should not place undue reliance on our forward-looking statements or

information. Factors that could cause actual events or results expressed or

implied by such forward looking statements to differ materially from any

future results expressed or implied by such statements or information

include, but are not limited to: uncertainties related to early stage of

technology and product development; dependence on corporate collaborations;

uncertainties as to future expense levels and the possibility of

unanticipated costs or expenses or cost overruns, the possibility that

opportunities will arise that require more cash than presently anticipated

and other uncertainties related to predictions of future cash requirements;

uncertainties as to the requirement that a drug be found to be safe and

effective after extensive clinical trials and the possibility that the

results of such trials, if commenced and completed, will not establish the

safety or efficacy of our products; risks relating to requirements for

approvals by government agencies such as the FDA and/or Health Canada

before products can be tested in clinical trials and ultimately marketed;

the possibility that such government agency approvals will not be obtained

in a timely manner or at all or will be conditioned in a manner that would

impair our ability to advance development and/or market the product

successfully; management of growth; dependence on key personnel; the

possibility that we will not successfully develop any products; the

possibility that advances by competitors will cause our proposed products

not to be viable, the risk that our patents could be invalidated or

narrowed in scope by judicial actions or that our technology could infringe

the patent or other intellectual property rights of third parties; the

possibility that any products successfully developed by us will not achieve

market acceptance; and other risks and uncertainties which may not be

described herein. Certain of these factors and other factors are described

in detail in the Company's Annual Information Form and Annual Report on

Form 20-F and other filings with the Canadian securities regulatory

authorities and the U.S. Securities & Exchange Commission. Forward-looking

statements are based on our current expectations and MIGENIX assumes no

obligations to update such information to reflect later events or

developments.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

SOURCE MIGENIX Inc.

http://www.prnewswire.com/news/index_mail.shtml?Account=HEA & Template=hea_ind.htm\

l

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

MIGENIX Completes Enrollment of Celgosivir (MX-3253) Phase IIb HCV

Combination Study

VANCOUVER/SAN DIEGO, June 15 /PRNewswire-FirstCall/ - MIGENIX Inc.

(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious

and degenerative diseases, has completed enrollment in a Phase IIb study of

celgosivir (MX-3253) in combination with PEG-INTRON® (peginterferon alfa-

2b), and PEGETRON (peginterferon alfa-2b plus ribavirin) for the

treatment of hepatitis C virus (HCV) infection in genotype 1 patients who

were non- responders or partial responders to previous treatment with

pegylated interferon-based therapy. A total of 57 subjects have been

enrolled. The subjects will be treated for 12 weeks and results are

expected to be available in October 2006. This study is being supported in

part through an agreement with Schering-Plough.

AnnKatrin sen, M.D., Vice President of Clinical Development for

MIGENIX commented, " With 57 patients enrolled, this study is well-powered

to detect a treatment effect as measured by the change in mean viral load

over a 12-week treatment period. This proof-of-concept study in conjunction

with our planned viral kinetic study in naive patients will provide

substantial information about the benefit of celgosivir in combination with

peginterferon alfa-2b, with and/or without ribavirin in the treatment of

HCV. "

Jim DeMesa, M.D., President and CEO of MIGENIX added, " During the next

12 months we expect results from two Phase II studies of celgosivir in the

treatment of HCV patients and a pivotal Phase III study of CPI-226 in the

prevention of catheter-related infections. These clinical results, along

with the progress we are making in advancing several pipeline programs,

provide us many value-driving opportunities for the future. "

About Celgosivir

Celgosivir is an alpha-glucosidase I inhibitor and is currently the

only oral anti-HCV drug in clinical development that acts on host-directed

glycosylation. In preclinical studies, celgosivir has demonstrated strong

synergy with interferon-alpha (with or without ribavirin) and other drugs

in development for the treatment of HCV (e.g. polymerase inhibitors) and

has the potential to be included as part of a combination therapeutic

approach to improve efficacy.

About the Phase IIb Combination Study in HCV Non-Responder/Partial

Responder Patients

The Phase IIb study is designed to determine over 12 weeks of treatment

the efficacy, safety, and tolerability of celgosivir in combination with

PEG-INTRON® (peginterferon alfa-2b), and PEGETRON (peginterferon

alfa-2b plus ribavirin), in HCV-positive (genotype 1) patients who were

non-responders or partial responders to previous treatment with pegylated

interferon-based therapy. The study is a randomized, multi-center,

active-controlled, 12 week evaluation of celgosivir in three treatment arms

(up to 20 patients in each treatment arm): (i) celgosivir plus PEGETRON

(3-way combination); (ii) celgosivir plus PEG-INTRON® (2-way

combination); and (iii) placebo plus peginterferon alfa-2b plus ribavirin

(control). A total of 57 subjects have been enrolled into the study. The

Phase IIb study is supported in part through an agreement with

Schering-Plough Corporation. Schering-Plough is contributing (a) the supply

of PEG-INTRON® and PEGETRON and ( certain technical and laboratory

support and other services for the studies. In addition, the agreement

grants Schering-Plough limited periods of exclusivity for data review

following the clinical trial results and for the negotiation of a license

agreement.

About HCV

HCV, the most common chronic blood-borne infection in the United

States, causes inflammation of the liver and may progress to more serious

complications such as cirrhosis of the liver, liver cancer and death.

Approximately 2.7 million people in the United States are chronically

infected with HCV, and the Centers for Disease Control and Prevention (CDC)

estimates that by the year 2010, the number of deaths attributed annually

to HCV could surpass that due to HIV/AIDS in the US. Worldwide, the World

Health Organization estimates that 170 million individuals have chronic HCV

infection, with 3 to 4 million new infections each year.

Therapy for HCV currently employs a drug combination approach, which is

anticipated to continue in the future. The current standard of care for

chronic hepatitis C is pegylated interferon combined with ribavirin, which

fails to provide a satisfactory outcome for approximately 50% of patients

infected with HCV genotype 1. In addition, these drugs can cause

significant side effects that limit tolerance to therapy, or a frequent

lack of sustained treatment response.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and

enriching life by developing and commercializing drugs in the areas of

infectious and degenerative diseases. The Company's clinical programs

include drug candidates for the treatment of chronic hepatitis C infections

(Phase II), the prevention of catheter-related infections (Phase III), the

treatment of neurodegenerative diseases (Phase I) and the treatment of acne

(Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada

with US operations in San Diego, California. Additional information can be

found at http://www.migenix.com.

" Jim DeMesa "

M. DeMesa, M.D.

President & CEO

CONTACTS

Art Ayres Dian Griesel, Ph.D.

MIGENIX Inc. Investor Relations Group

Tel: (604) 221-9666 Ext. 233 Tel: (212) 825-3210

aayres@... Theproteam@...

FORWARD-LOOKING STATEMENTS

Certain statements in this news release contain forward-looking

statements or information under applicable Canadian and United States

securities legislation. All statements or information other than statements

of historical fact may be deemed to be forward-looking statements or

information. Forward-looking statements frequently, but not always, use the

words " intends " , " plans " , " believes " , " anticipates " or " expects " or similar

words; that events " will " , " may " , " could " or " should " occur; and/or include

statements or information concerning our strategies, goals, plans and

expectations. Forward-looking statements or information in this news

release include, but are not limited to statements or information

concerning: results from the celgosivir Phase IIb combination study in

non-responder and partial responder HCV infected patients being available

in October 2006; and during the next 12 months having results from two

Phase II studies of celgosivir in the treatment of HCV patients and from a

pivotal Phase III study of CPI-226 in the prevention of catheter-related

infections. We may not actually achieve the plans, intentions or

expectations disclosed in our forward-looking statements or information and

you should not place undue reliance on our forward-looking statements or

information. Factors that could cause actual events or results expressed or

implied by such forward looking statements to differ materially from any

future results expressed or implied by such statements or information

include, but are not limited to: uncertainties related to early stage of

technology and product development; dependence on corporate collaborations;

uncertainties as to future expense levels and the possibility of

unanticipated costs or expenses or cost overruns, the possibility that

opportunities will arise that require more cash than presently anticipated

and other uncertainties related to predictions of future cash requirements;

uncertainties as to the requirement that a drug be found to be safe and

effective after extensive clinical trials and the possibility that the

results of such trials, if commenced and completed, will not establish the

safety or efficacy of our products; risks relating to requirements for

approvals by government agencies such as the FDA and/or Health Canada

before products can be tested in clinical trials and ultimately marketed;

the possibility that such government agency approvals will not be obtained

in a timely manner or at all or will be conditioned in a manner that would

impair our ability to advance development and/or market the product

successfully; management of growth; dependence on key personnel; the

possibility that we will not successfully develop any products; the

possibility that advances by competitors will cause our proposed products

not to be viable, the risk that our patents could be invalidated or

narrowed in scope by judicial actions or that our technology could infringe

the patent or other intellectual property rights of third parties; the

possibility that any products successfully developed by us will not achieve

market acceptance; and other risks and uncertainties which may not be

described herein. Certain of these factors and other factors are described

in detail in the Company's Annual Information Form and Annual Report on

Form 20-F and other filings with the Canadian securities regulatory

authorities and the U.S. Securities & Exchange Commission. Forward-looking

statements are based on our current expectations and MIGENIX assumes no

obligations to update such information to reflect later events or

developments.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

SOURCE MIGENIX Inc.

http://www.prnewswire.com/news/index_mail.shtml?Account=HEA & Template=hea_ind.htm\

l

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

MIGENIX Completes Enrollment of Celgosivir (MX-3253) Phase IIb HCV

Combination Study

VANCOUVER/SAN DIEGO, June 15 /PRNewswire-FirstCall/ - MIGENIX Inc.

(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious

and degenerative diseases, has completed enrollment in a Phase IIb study of

celgosivir (MX-3253) in combination with PEG-INTRON® (peginterferon alfa-

2b), and PEGETRON (peginterferon alfa-2b plus ribavirin) for the

treatment of hepatitis C virus (HCV) infection in genotype 1 patients who

were non- responders or partial responders to previous treatment with

pegylated interferon-based therapy. A total of 57 subjects have been

enrolled. The subjects will be treated for 12 weeks and results are

expected to be available in October 2006. This study is being supported in

part through an agreement with Schering-Plough.

AnnKatrin sen, M.D., Vice President of Clinical Development for

MIGENIX commented, " With 57 patients enrolled, this study is well-powered

to detect a treatment effect as measured by the change in mean viral load

over a 12-week treatment period. This proof-of-concept study in conjunction

with our planned viral kinetic study in naive patients will provide

substantial information about the benefit of celgosivir in combination with

peginterferon alfa-2b, with and/or without ribavirin in the treatment of

HCV. "

Jim DeMesa, M.D., President and CEO of MIGENIX added, " During the next

12 months we expect results from two Phase II studies of celgosivir in the

treatment of HCV patients and a pivotal Phase III study of CPI-226 in the

prevention of catheter-related infections. These clinical results, along

with the progress we are making in advancing several pipeline programs,

provide us many value-driving opportunities for the future. "

About Celgosivir

Celgosivir is an alpha-glucosidase I inhibitor and is currently the

only oral anti-HCV drug in clinical development that acts on host-directed

glycosylation. In preclinical studies, celgosivir has demonstrated strong

synergy with interferon-alpha (with or without ribavirin) and other drugs

in development for the treatment of HCV (e.g. polymerase inhibitors) and

has the potential to be included as part of a combination therapeutic

approach to improve efficacy.

About the Phase IIb Combination Study in HCV Non-Responder/Partial

Responder Patients

The Phase IIb study is designed to determine over 12 weeks of treatment

the efficacy, safety, and tolerability of celgosivir in combination with

PEG-INTRON® (peginterferon alfa-2b), and PEGETRON (peginterferon

alfa-2b plus ribavirin), in HCV-positive (genotype 1) patients who were

non-responders or partial responders to previous treatment with pegylated

interferon-based therapy. The study is a randomized, multi-center,

active-controlled, 12 week evaluation of celgosivir in three treatment arms

(up to 20 patients in each treatment arm): (i) celgosivir plus PEGETRON

(3-way combination); (ii) celgosivir plus PEG-INTRON® (2-way

combination); and (iii) placebo plus peginterferon alfa-2b plus ribavirin

(control). A total of 57 subjects have been enrolled into the study. The

Phase IIb study is supported in part through an agreement with

Schering-Plough Corporation. Schering-Plough is contributing (a) the supply

of PEG-INTRON® and PEGETRON and ( certain technical and laboratory

support and other services for the studies. In addition, the agreement

grants Schering-Plough limited periods of exclusivity for data review

following the clinical trial results and for the negotiation of a license

agreement.

About HCV

HCV, the most common chronic blood-borne infection in the United

States, causes inflammation of the liver and may progress to more serious

complications such as cirrhosis of the liver, liver cancer and death.

Approximately 2.7 million people in the United States are chronically

infected with HCV, and the Centers for Disease Control and Prevention (CDC)

estimates that by the year 2010, the number of deaths attributed annually

to HCV could surpass that due to HIV/AIDS in the US. Worldwide, the World

Health Organization estimates that 170 million individuals have chronic HCV

infection, with 3 to 4 million new infections each year.

Therapy for HCV currently employs a drug combination approach, which is

anticipated to continue in the future. The current standard of care for

chronic hepatitis C is pegylated interferon combined with ribavirin, which

fails to provide a satisfactory outcome for approximately 50% of patients

infected with HCV genotype 1. In addition, these drugs can cause

significant side effects that limit tolerance to therapy, or a frequent

lack of sustained treatment response.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and

enriching life by developing and commercializing drugs in the areas of

infectious and degenerative diseases. The Company's clinical programs

include drug candidates for the treatment of chronic hepatitis C infections

(Phase II), the prevention of catheter-related infections (Phase III), the

treatment of neurodegenerative diseases (Phase I) and the treatment of acne

(Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada

with US operations in San Diego, California. Additional information can be

found at http://www.migenix.com.

" Jim DeMesa "

M. DeMesa, M.D.

President & CEO

CONTACTS

Art Ayres Dian Griesel, Ph.D.

MIGENIX Inc. Investor Relations Group

Tel: (604) 221-9666 Ext. 233 Tel: (212) 825-3210

aayres@... Theproteam@...

FORWARD-LOOKING STATEMENTS

Certain statements in this news release contain forward-looking

statements or information under applicable Canadian and United States

securities legislation. All statements or information other than statements

of historical fact may be deemed to be forward-looking statements or

information. Forward-looking statements frequently, but not always, use the

words " intends " , " plans " , " believes " , " anticipates " or " expects " or similar

words; that events " will " , " may " , " could " or " should " occur; and/or include

statements or information concerning our strategies, goals, plans and

expectations. Forward-looking statements or information in this news

release include, but are not limited to statements or information

concerning: results from the celgosivir Phase IIb combination study in

non-responder and partial responder HCV infected patients being available

in October 2006; and during the next 12 months having results from two

Phase II studies of celgosivir in the treatment of HCV patients and from a

pivotal Phase III study of CPI-226 in the prevention of catheter-related

infections. We may not actually achieve the plans, intentions or

expectations disclosed in our forward-looking statements or information and

you should not place undue reliance on our forward-looking statements or

information. Factors that could cause actual events or results expressed or

implied by such forward looking statements to differ materially from any

future results expressed or implied by such statements or information

include, but are not limited to: uncertainties related to early stage of

technology and product development; dependence on corporate collaborations;

uncertainties as to future expense levels and the possibility of

unanticipated costs or expenses or cost overruns, the possibility that

opportunities will arise that require more cash than presently anticipated

and other uncertainties related to predictions of future cash requirements;

uncertainties as to the requirement that a drug be found to be safe and

effective after extensive clinical trials and the possibility that the

results of such trials, if commenced and completed, will not establish the

safety or efficacy of our products; risks relating to requirements for

approvals by government agencies such as the FDA and/or Health Canada

before products can be tested in clinical trials and ultimately marketed;

the possibility that such government agency approvals will not be obtained

in a timely manner or at all or will be conditioned in a manner that would

impair our ability to advance development and/or market the product

successfully; management of growth; dependence on key personnel; the

possibility that we will not successfully develop any products; the

possibility that advances by competitors will cause our proposed products

not to be viable, the risk that our patents could be invalidated or

narrowed in scope by judicial actions or that our technology could infringe

the patent or other intellectual property rights of third parties; the

possibility that any products successfully developed by us will not achieve

market acceptance; and other risks and uncertainties which may not be

described herein. Certain of these factors and other factors are described

in detail in the Company's Annual Information Form and Annual Report on

Form 20-F and other filings with the Canadian securities regulatory

authorities and the U.S. Securities & Exchange Commission. Forward-looking

statements are based on our current expectations and MIGENIX assumes no

obligations to update such information to reflect later events or

developments.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

SOURCE MIGENIX Inc.

http://www.prnewswire.com/news/index_mail.shtml?Account=HEA & Template=hea_ind.htm\

l

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/